Skip to content

Dossier · CBZ · Dormant

CBZ · CBIZ, Inc. · Stock research

Last analysed ·

Current thesis

Activist-driven re-rate on a cheap professional-services roll-up: Reference Equity's July 7 letter to halt buybacks and resume M&A drove a +9.3% pop, and the tape is +36% in 30 days straight into a July 29 earnings binary that confirms or breaks the story.

Invalidation trigger

A weekly close below $36 surrenders the post-activist-letter breakout base and signals the re-rate leg failed; secondarily, a July 29 Q2 revenue miss under $704.9M or a FY guide cut below $4.00 EPS confirms the break.

Thesis status

Open commitment catalyst in 3dscored if the trigger above fires How this is scored →

Latest analysis and events for CBZ —

As of 2026-07-25, orbyd's latest analysis for CBIZ, Inc. (CBZ): Activist-driven re-rate on a cheap professional-services roll-up: Reference Equity's July 7 letter to halt buybacks and resume M&A drove a +9.3% pop, and the tape is +36% in 30 days straight into a July 29 earnings binary that confirms or breaks the story.

Invalidation trigger: A weekly close below $36 surrenders the post-activist-letter breakout base and signals the re-rate leg failed; secondarily, a July 29 Q2 revenue miss under $704.9M or a FY guide cut below $4.00 EPS confirms the break.

Next dated event on file: — catalyst in 3d.

Current Thesis

Activist-driven re-rate on a cheap professional-services roll-up. Reference Equity's July 7 letter to halt buybacks and resume the M&A engine drove a +9.3% pop, and the tape is +36% in 30 days straight into a July 29 earnings binary that either confirms the growth-restoring story or reprices the whole move. The multiple is genuinely cheap (~10.4x forward vs peers 22–29x), but the setup is stretched into a catalyst it cannot yet see, and consensus price target already sits at spot.

Bullish and bearish views on CBIZ, Inc.

The model's bull view on CBIZ, Inc. (CBZ), in brief: Activist campaign is live and specific: Reference Equity (long-only, PM Ryan Bunn) published a July 7, 2026 letter + deck demanding CBIZ halt share repurchases, resume the acquisition program, and raise equity to fund growth. The bear view: Binary earnings in 3 trading days: Q2/first-half print July 29 after close (call 5:00pm ET), consensus Q2 EPS $0.81 and revenue $704.9M. Both cases follow in full.

Bull Case

  • Activist campaign is live and specific: Reference Equity (long-only, PM Ryan Bunn) published a July 7, 2026 letter + deck demanding CBIZ halt share repurchases, resume the acquisition program, and raise equity to fund growth. Stock +9.3% on disclosure; Bloomberg and Bloomberg Tax covered it July 7.
  • Valuation gap is the entire pitch: ~14–17x trailing P/E and ~10.4x forward vs accounting/advisory peers at 22–29x. Any move toward a peer multiple is a large re-rate.
  • Guidance sits above the street: FY2026 guide of EPS $4.00–4.10 vs consensus $3.79, revenue $2.8–2.9B (issued ~May 1, 2026).
  • Post-Marcum scale is showing in the numbers: TTM revenue +28.3% YoY, net income +77.5% YoY.
  • Recovery momentum: +36.4% over 30 days and +38.8% over 90 days into $42.63 on July 24 (+5.9% that session).

Bear Case

  • Binary earnings in 3 trading days: Q2/first-half print July 29 after close (call 5:00pm ET), consensus Q2 EPS $0.81 and revenue $704.9M. A miss on Marcum pricing or integration reprices the activist pop instantly.
  • The obvious upside looks captured: consensus PT $42.60 vs price $42.63 mainstream sell-side models roughly zero further room from here.
  • Still a wreck on the tape: −43% over 12 months, 52-week range $24.29–$77.91. The current $42 is a bounce off a crash, not a fresh high.
  • Marcum overhang persists: pricing pressure and elevated post-deal leverage are the exact concerns cited in July 20 valuation-debate coverage. The activist remedy raise equity is itself dilutive.
  • The "worth over 2x" and +211% outlier targets (Simply Wall St narrative, nemo.money, July 2026) stand against a consensus target sitting at spot.

Setup & Price Structure

  • $42.63 on July 24, having reclaimed the low-$30s base (the level ~30 days prior was near $31) after the July 7 activist catalyst.
  • Post-activist breakout base sits ~$36–37 (July 10 traded $37.79 mid-move). That shelf is the line the re-rate leg has to defend.
  • Stretched profile: a +36% 30-day advance running directly into a binary print strength that is an event pop, not a durable accelerating trend.
  • Overhead: the $77.91 52-week high is distant; nearest friction is the round $45–48 zone just above the consensus-target cluster near $42.60.

Catalyst Calendar (next 30 days)

  • 2026-07-29 (after close): Q2 and first-half 2026 results; call 5:00pm ET. Consensus EPS $0.81, revenue $704.9M, FY bar $4.00–4.10 EPS. This is the binary.
  • Ongoing: Reference Equity campaign watch for a board response, any 13D-style escalation, or an actual M&A restart / capital-raise announcement following the July 7 letter.
  • The reaffirm-or-raise call against the $4.00–4.10 EPS guide is the single number that governs the post-print move.

What Would Change Our Mind

  • A weekly close below $36 surrenders the post-activist-letter breakout base and signals the re-rate leg has failed, with the July 7 pop round-tripping.
  • A July 29 revenue miss under $704.9M, or a FY guide cut below $4.00 EPS, breaks the growth-restoring leg on the fundamentals.
  • The board rejecting the activist with no acquisition restart removes the special-situation catalyst entirely.
  • Inverted: a clean beat plus guide raise plus an explicit M&A restart converts this from stretched-into-print to a fresh accelerating leg worth engaging on a defined higher-low.

Correlation Notes

  • Moves with professional-services / accounting-advisory consolidators and staffing-consulting names; sensitive to middle-market client spend and the hiring cycle.
  • The benefits & insurance segment lends partial defensive ballast, but this is not a managed-care or health-services name despite the legacy theme tag carried in from theme discovery.
  • Behaves as an activist special situation: correlated more to event and catalyst flow than to broad-market beta in any given week.
  • Elevated post-Marcum leverage keeps it rate-sensitive; a tightening macro impulse pressures the multiple that the entire bull case depends on.

Notes

  • EARNINGS BLACKOUT: Q2/first-half 2026 prints 2026-07-29 after close, call 5:00pm ET binary; avoid fresh entries into the print (consensus EPS $0.81, rev $704.9M, FY bar $4.00-4.10 EPS).
  • THEME MIS-TAG: seeded 'managed-care-health-services' is wrong CBIZ is a professional-services / accounting-advisory firm (Marcum roll-up) with a benefits & insurance segment, not a managed-care name.
  • Activist: Reference Equity (long-only, PM Ryan Bunn), letter+deck 2026-07-07 halt buybacks, resume M&A, raise equity. Stock +9.3% on disclosure.
  • Valuation: ~10.4x forward / ~14-17x TTM P/E vs accounting-advisory peers 22-29x; consensus PT ~$42.60 sits at spot. 52-week range $24.29-$77.91, -43% over 12 months.

Related · shared themes

See also · stocks to watch